Abstract: Systems and methods are disclosed herein for ion exchange wherein process fluid is injected at multiple points within the ion exchange vessel simultaneously, allowing the contaminants and/or the contaminated process fluid to be distributed homogeneously throughout the ion exchange media. These systems and methods may be implemented in one or more of fixed, mobile, and modular embodiments.

Abstract: Methods, apparatus, systems, and articles of manufacture are disclosed to determine mutex entropy for malware classification. An example apparatus includes interface circuitry to access a mutex associated with a software application, the mutex to include a mutex identifier string, normalizer circuitry to normalize the mutex identifier string, character probability circuitry to determine character probabilities of characters within the normalized mutex identifier string, the character probabilities based on a historical mutex character distribution, entropy calculator circuitry to calculate an entropy value for the mutex based on the character probabilities, classifier circuitry to classify the mutex as clean or malicious based on the entropy value, and protector circuitry to mitigate malicious attacks based on the classification.

Abstract: The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

Abstract: There is disclosed in one example a computing apparatus, including: a hardware platform including a processor circuit and a memory circuit; first means for accessing a machine learning engine; second means for accessing a user interface; and instructions encoded within the memory to instruct the processor to: load into the machine learning engine via the first means an object prevalence model, including an enterprise-specific prevalence model; provide to the machine learning engine an object set from the enterprise; identify an enterprise-novel object from the object set; solicit and receive via the second means user-sourced feedback for the enterprise-novel object; and act according to the user-sourced feedback.

Abstract: The present invention is based on the identification of a G-protein coupled receptor (GPCR) that is expressed predominantly in the brain and placenta and nucleic acid molecules that encoded the GPCR, which is referred to herein as the hCAR protein and hCAR gene respectively (for human Constitutively Active Receptor). Based on this identification, the present invention provides: (1) isolated hCAR protein; (2) isolated nucleic acid molecules that encode an hCAR protein; (3) antibodies that selectively bind to the hCAR protein; (4) methods of isolating allelic variants of the hCAR protein and gene; (5) methods of identifying cells and tissues that express the hCAR protein/gene; (6) methods of identifying agents and cellular compounds that bind to the hCAR protein; (7) methods of identifying agents that modulate the expression of the hCAR gene; and (8) methods of modulating the activity of the hCAR protein in a cell or organism.

Abstract: The present invention is based on the identification of a G-protein coupled receptor (GPCR) that is expressed predominantly in the brain and placenta and nucleic acid molecules that encoded the GPCR, which is referred to herein as the hCAR protein and hCAR gene respectively (for human Constitutively Active Receptor). Based on this identification, the present invention provides: (1) isolated hCAR protein; (2) isolated nucleic acid molecules that encode an hCAR protein; (3) antibodies that selectively bind to the hCAR protein; (4) methods of isolating allelic variants of the hCAR protein and gene; (5) methods of identifying cells and tissues that express the hCAR protein/gene; (6) methods of identifying agents and cellular compounds that bind to the hCAR protein; (7) methods of identifying agents that modulate the expression of the hCAR gene; and (8) methods of modulating the activity of the hCAR protein in a cell or organism.

Abstract: Novel mGluR5M polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length mGluR5M proteins, the invention further provides isolated mGluR5M fusion proteins, antigenic peptides and anti-mGluR5M antibodies. The invention also provides mGluR5M nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a mGluR5M gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.